Mechanistically, kayadiol downregulates SLC7A11 and GPX4 expression by using p53 as a key mediator, which is critical to reverse chemotherapy resistance in NKTCL cells (Table 1) [130]. Here, GPX4 is linked to extranodal nasal NK/T cell lymphoma.